The dataset contains 192 anti-cancer combinations (both approved drugs and investigational compounds) tested in 8x8 dose-response matrix designs in 10 breast cancer cell lines (BT-549, CAL-148, CAL-51, CAL-85-1, DU-4475, HCC-1599, MDA-Mi-231, MDA-MD-436, MFM-223, and MCF10A) as well as 18 anti-cancer combinations tested in 8x8 dose-response matrix designs in HEK293 (embryonic kidney), HeLa (cervical cancer) and Hep G2 (hepatocellular cancer) cell lines. For more information please refer to original paper: [to be filled]
